IP Library Granted Patent US 7,026,359
Granted Patent B1
US 7,026,359 · App. 10/018,398 · Granted Apr 11, 2006

Utilization of a highly fluorinated oligomeric alkane in ophthalmology

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,026,359
App. No.
10/018,398
Granted
Apr 11, 2006
Kind
B1
Abstract

The invention relates to the utilization of a highly fluorinated oligomeric alkane as a therapeutic agent in ophthalmology, the alkane having the general formula [—R F (CH 2 ) n CR 1 —CR 2 —] x , wherein R F is a linear or branched perfluorinated alkyl chain C 2 F 5 to C 12 F 23 , R 1 and R 2 are independently selected from the group consisting of H, CH 3 , C 2 H 5 and C 3 H 7 , n is selected from the numbers 0, 1 and 2, and x is a number between 2 and 6, with a molar mass of at least 750. According to the invention, a pharmacological agent is provided that is used in ophthalmology and that causes little or no damage to the retina even when used over a long period.

Claims (15)

1. A method of treating an eye comprising the step of applying at least one highly fluorinated oligomeric compound of the general formula

wherein

R F is a linear or branched perfluorinated alkyl chain C 2 F 5 to C 12 F 25 ,

R for each position is independently selected from the group H, CH 3 , C 2 H 5 and C 3 H 7 ,

n is selected from the integers 0, 1 and 2, and

x is an integer from 2 to 6,

having a molecular weight of at least 750

to an eye as an ophthalmologic treating agent, wherein the application to the eye is as one of:

a) a vitreous body substitute,

b) a liquid implant,

c) a tear substitute,

d) a carrier of a pharmacological agent mixed with the highly fluorinated oligomeric compound before applying to the eye, and

e) a retina tamponade.

2. The method of claim 1 wherein a plurality of different ones of said highly fluorinated oligomeric compounds are mixed together before applying to the eye.

3. The method of claim 1 wherein said highly fluorinated oligomeric compound is a component of a pharmacological preparation that is applied to the eye.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
MERGER Recorded May 31, 2013
From: BAUSCH & LOMB SURGICAL, INC.
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 030522/0865 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Mar 26, 2008
From: BAUSCH & LOMB INCORPORATED; WP PRISM INC.; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; IOLAB CORPORATION; RHC HOLDINGS, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC
To: CREDIT SUISSE
Reel/Frame 020733/0765 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2003
From: PHARM PUR GMBH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 013863/0822 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2002
From: GROSS, UDO; MENZ, DIRK-HENNING; KEMNITZ, ERHARD; HOERAUF, HANS; KOBUCH, KARIN
To: PHARM PUR GMBH
Reel/Frame 012758/0281 →